Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4062 ARTÍCULOS , VIENDO DEL 1681 AL 1695

Osteopathic manipulative treatment in neurological diseases: Systematic review of the literature

Cerritelli F, Ruffini N, Lacorte E, Vanacore N.

J Neurol Sci. 2016 Oct 15;369:333-341. doi: 10.1016/j.jns.2016.08.062. Epub 2016 Aug 30.

Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders

Ingelsson M.

Front Neurosci. 2016 Sep 5;10:408. doi: 10.3389/fnins.2016.00408. eCollection 2016.

Protein Kinases and Parkinson's Disease

Mehdi SJ, Rosas-Hernandez H, Cuevas E, Lantz SM, Barger SW, Sarkar S, Paule MG, Ali SF, Imam SZ.

Int J Mol Sci. 2016 Sep 20;17(9):1585. doi: 10.3390/ijms17091585.

An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics

Javed H, Kamal MA, Ojha S.

CNS Neurol Disord Drug Targets. 2016;15(10):1240-1252. doi: 10.2174/1871527315666160920160512.

[Patients' Perspective on Parkinson Disease Therapies: Comparative Results of Large-scale Surveys in 2008 and 2013 in Japan]

Fujimoto KI, Murata M, Hattori N, Kondo T.

Brain Nerve. 2016 Sep;68(9):1087-1098. doi: 10.11477/mf.1416200556.

Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis

Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y.

JAMA Neurol. 2016 Nov 1;73(11):1316-1324. doi: 10.1001/jamaneurol.2016.2742.

Cytokines as Potential Biomarkers of Parkinson Disease

Alcalay RN.

JAMA Neurol. 2016 Nov 1;73(11):1282-1284. doi: 10.1001/jamaneurol.2016.3335.

Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson's Disease

Grimmig B, Morganti J, Nash K, Bickford PC.

Brain Sci. 2016 Sep 23;6(4):41. doi: 10.3390/brainsci6040041.

Medical Management of Parkinson's Disease after Initiation of Deep Brain Stimulation

Fasano A, Appel-Cresswell S, Jog M, Zurowkski M, Duff-Canning S, Cohn M, Picillo M, Honey CR, Panisset M, Munhoz RP.

Can J Neurol Sci. 2016 Sep;43(5):626-34. doi: 10.1017/cjn.2016.274.

Effect of cumulative repetitive transcranial magnetic stimulation on freezing of gait in patients with atypical Parkinsonism: A pilot study

Chang WH, Kim MS, Cho JW, Youn J, Kim YK, Kim SW, Lee A, Kim YH.

J Rehabil Med. 2016 Oct 12;48(9):824-828. doi: 10.2340/16501977-2140.

A case of sudden deterioration in Parkinson disease

Umemoto G, Fujioka S, Yanamoto S, Fukae J, Tsuboi Y.

Neurology. 2016 Sep 27;87(13):1422. doi: 10.1212/WNL.0000000000003163.

Deep Brain Stimulation and Gene Expression Alterations in Parkinson's Disease

Mohammadi A, Mehdizadeh AR.

J Biomed Phys Eng. 2016 Jun 1;6(2):47-50. eCollection 2016 Jun.

Neurotoxic Non-proteinogenic Amino Acid β-N-Methylamino-L-alanine and Its Role in Biological Systems

Popova AA, Koksharova OA.

Biochemistry (Mosc). 2016 Aug;81(8):794-805. doi: 10.1134/S0006297916080022.

Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease

Török N, Majláth Z, Szalárdy L, Vécsei L.

Expert Opin Investig Drugs. 2016 Nov;25(11):1281-1294. doi: 10.1080/13543784.2016.1237501. Epub 2016 Oct 8.

Treatment Options for Urogenital Dysfunction in Parkinson's Disease

Batla A, Tayim N, Pakzad M, Panicker JN.

Curr Treat Options Neurol. 2016 Oct;18(10):45. doi: 10.1007/s11940-016-0427-0.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias